Literature DB >> 19676144

Sensitive and specific ELISA coated by TpN15-TpN17-TpN47 fusion protein for detection of antibodies to Treponema pallidum.

Ai Hua Sun1, Ya Fei Mao, Ye Hu, Qi Sun, Jie Yan.   

Abstract

BACKGROUND: We constructed an artificial fusion gene tpN15-17-47 and then used the prokaryotic expression fusion protein rTpN15-17-47 as the coated antigen to establish a new enzyme-linked immunosorbent assay (ELISA) for serological diagnosis of syphilis.
METHODS: tpN15, tpN17, and tpN47 genes were amplified separately by polymerase chain reaction (PCR) and then assembled into a fusion gene coding a trigeminy protein antigen by primer linking PCR. The target recombinant protein antigens rTpN15, rTpN17, rTpN-47, and rTpN15-17-47 were expressed and then purified antigens were immobilized on the surface of microplate wells for detecting Treponema pallidum-specific antibodies by ELISAs.
RESULTS: The relative positive rate of rTpN15-17-47-ELISA in 965 serum specimens of syphilis patients was 99.5%, which was higher than that of the T. pallidum hemagglutination assay (TPHA) (98.3%) (p<0.05) and much higher than that of the rTpN15-ELISA (83.1%), the rTpN17-ELISA (84.4%), the rTpN47-ELISA (82.1%), and the toluidine red unheated serum test (TRUST) (72.2%) (p<0.01). All the ELISAs and the TPHA in detecting serum specimens from 62 cases with systemic lupus erythematosus (SLE), 86 cases with rheumatic arthritis (RA), and 250 healthy cases were negative, but the TRUST was positive in five cases with SLE, seven cases with RA, and two healthy cases.
CONCLUSIONS: The rTpN15-17-47-ELISA is a sensitive and specific serological screening or a diagnostic method for syphilis in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19676144     DOI: 10.1515/CCLM.2009.071

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Tp0684, Tp0750, and Tp0792 Recombinant Proteins as Antigens for the Serodiagnosis of Syphilis.

Authors:  Júlio Henrique Ferreira de Sá Queiroz; Marcelo Dos Santos Barbosa; Lais Gonçalves Ortolani Miranda; Natasha Rodrigues de Oliveira; Odir Antônio Dellagostin; Silvana Beutinger Marchioro; Simone Simionatto
Journal:  Indian J Microbiol       Date:  2022-04-19

2.  Evaluation of the recombinant protein TpF1 of Treponema pallidum for serodiagnosis of syphilis.

Authors:  Chuanhao Jiang; Feijun Zhao; Jinhong Xiao; Tiebing Zeng; Jian Yu; Xiaohua Ma; Haiying Wu; Yimou Wu
Journal:  Clin Vaccine Immunol       Date:  2013-08-14

3.  Europium nanoparticle-based high performing immunoassay for the screening of treponemal antibodies.

Authors:  Sheikh M Talha; Jukka Hytönen; Adam Westhorpe; Sushil Kumar; Navin Khanna; Kim Pettersson
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

Review 4.  Efforts in blood safety: Integrated approach for serological diagnosis of syphilis.

Authors:  Linda Sommese; Maria Rosaria De Pascale; Maria Capuano; Claudio Napoli
Journal:  Asian J Transfus Sci       Date:  2016 Jan-Jun

5.  Serological evaluation of antigen Tp0693 for diagnosis of syphilis.

Authors:  Li Zhang; Meixia Deng; Xiaohong Zhang; Weiguo Yin; Wen Liu; Xi Luo; Jie Yang; Fei Chen; Feijun Zhao
Journal:  Exp Ther Med       Date:  2017-09-21       Impact factor: 2.447

Review 6.  Novel Treponema pallidum Recombinant Antigens for Syphilis Diagnostics: Current Status and Future Prospects.

Authors:  Aleksey Kubanov; Anastassia Runina; Dmitry Deryabin
Journal:  Biomed Res Int       Date:  2017-04-24       Impact factor: 3.411

7.  Performance of Treponema pallidum recombinant proteins in the serological diagnosis of syphilis.

Authors:  Ângelo Antônio Oliveira Silva; Ueriton Dias de Oliveira; Larissa de Carvalho Medrado Vasconcelos; Leonardo Foti; Leonardo Maia Leony; Ramona Tavares Daltro; Amanda Leitolis; Fernanda Washington de Mendonça Lima; Marco Aurélio Krieger; Nilson Ivo Tonin Zanchin; Fred Luciano Neves Santos
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.